- Home
- AEP vs MRNA Comparison
AEP vs MRNA Comparison
Compare AEP & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEP | MRNA |
|---|---|---|
| Founded | 1906 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5B | 61.6B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AEP | MRNA |
|---|---|---|
| Price | $119.75 | $189.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 23 |
| Target Price | ★ $142.53 | $119.56 |
| AVG Volume (30 Days) | 3.3M | ★ 11.7M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | 19.35 | ★ 21.77 |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $21,876,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $7.69 | $8.05 |
| Revenue Next Year | $6.70 | $16.07 |
| P/E Ratio | $74.56 | ★ N/A |
| Revenue Growth | ★ 10.93 | 4.29 |
| 52 Week Low | $112.54 | $22.28 |
| 52 Week High | $140.58 | $208.90 |
Technical Indicators
Market Signals| Indicator | AEP | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 69.29 |
| Support Level | $115.56 | $43.35 |
| Resistance Level | $120.45 | N/A |
| Average True Range (ATR) | 1.64 | 10.80 |
| MACD | -0.07 | 0.77 |
| Stochastic Oscillator | 15.42 | 76.61 |
Price Performance
Historical ComparisonAbout AEP American Electric Power Company Inc.
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 39% of AEP's capacity is coal, with the remainder from a mix of natural gas (28%), renewable energy and hydro (23%), nuclear (7%), and demand response (3%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.